The Impact of miRNA Expression on Colon Cancer Severity, Invasiveness, and Localization
Author:
Tâlvan Constantin-Dan1, Tâlvan Elena-Teodora1, Mohor Călin Ilie1, Budișan Liviuța2ORCID, Grecu Valentin3ORCID, Mihalache Manuela1, Neagoe Ioana Berindan2ORCID, Zănoagă Oana2, Oprinca George Călin1ORCID, Cristian Adrian Nicolae1
Affiliation:
1. Faculty of Medicine, “Lucian Blaga” University of Sibiu, 550169 Sibiu, Romania 2. Research Center for Functional Genomic, Biomedicine and Translational Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania 3. Faculty of Engineering, “Lucian Blaga” University of Sibiu, 550025 Sibiu, Romania
Abstract
Background/Objectives: Colorectal cancer (CRC) is a major global health concern with rising incidence and mortality. MicroRNAs (miRNAs) play key roles in tumor progression, invasion, and metastasis. This study aimed to analyze the expression of miR-101-3p, miR-106a-5p, and miR-326 in CRC patients and assess their association with tumor grading and tissue invasion. Methods: A total of 40 CRC patients were included in the study. miRNA expression levels were measured using quantitative reverse transcription PCR (qRT-PCR). Statistical analyses, including regression models, were performed to evaluate correlations between miRNA expression, tumor grade, and invasion patterns. Results: MiR-101-3p was significantly downregulated in advanced tumors, while miR-106a-5p expression peaked in Grade 2 CRC. MiR-326 expression was associated with organ metastasis. Regression models confirmed complex interaction patterns among these miRNAs, suggesting their potential role in CRC progression. Conclusions: These findings indicate that miR-101-3p, miR-106a-5p, and miR-326 are associated with CRC severity and invasion. Their expression patterns suggest potential utility as biomarkers for early detection and targeted therapies. Further studies with larger cohorts are needed to validate these results and explore their clinical applications.
Reference49 articles.
1. A review of treatment, risk factors, and incidence of colorectal cancer;Alaryani;Int. J. Appl. Pharm.,2022 2. Huang, J., Li, Z., Yao, L., Wang, M., Zhong, C.C., Zhang, L., Li, Y., Yuan, J., Lucero-Prisno, D.E., and Xu, W. (2024, January 10–11). IDDF2024-ABS-0435 Distinct patterns in the incidence of proximal and distal colon cancer subtypes: A comprehensive global analysis. Proceedings of the Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, China. 3. Spanos, C.P. (2022). Digestive System Malignancies, Elsevier. 4. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years;Vuik;Gut,2019 5. Zhang, Y., Zhang, X.-B., Ding, Y.-W., Kong, Y., Zhu, X.-F., Li, P.-H., Tian, Y., and Zhang, Q.-W. (2024). Distinct time trends in colorectal cancer incidence in countries with SDI levels from 1990 to 2019: An age–period–cohort analysis for the Global Burden of Disease 2019 study. Front. Public Health, 12.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|